Science developed in Chile when there are solid capacities and long-term vision
En los salones de una de las instituciones biomédicas más influyentes del mundo, un científico chileno recibió un reconocimiento que trasciende lo individual: el Distinguished PhD Alumnus Award del Albert Einstein College of Medicine llegó a Alexis Kalergis no como recompensa a una carrera solitaria, sino como testimonio de lo que ocurre cuando la ciencia se arraiga en comunidad, visión de largo plazo y propósito colectivo. Kalergis, director del Instituto Milenio de Inmunología e Inmunoterapia de Chile, se convierte en el primer chileno en recibir este galardón, reconocido por su rol en el desarrollo de vacunas, la investigación en enfermedades infecciosas y el liderazgo científico durante la pandemia. El honor, sin embargo, llega acompañado de una advertencia: los logros del presente no garantizan el florecimiento del futuro si no se construyen las condiciones estructurales que permitan a la próxima generación ir más lejos.
- Por primera vez en la historia, un científico chileno recibe el Distinguished PhD Alumnus Award del Albert Einstein College of Medicine, un hito que reposiciona a Chile en el mapa global de la biomedicina.
- El reconocimiento llega cargado de urgencia: Kalergis advierte que el ecosistema científico chileno enfrenta vulnerabilidades reales, especialmente en materia de financiamiento estable y continuidad institucional.
- Su vacuna contra el virus sincicial respiratorio avanza en ensayos clínicos internacionales, y su liderazgo durante el COVID-19 colocó a Chile entre los países con respuestas de vacunación más basadas en evidencia del mundo.
- Kalergis no celebra en solitario: enmarca el premio como prueba del potencial colectivo de la ciencia chilena, e interpela a universidades, industria y Estado a construir juntos la infraestructura que la innovación requiere.
- El verdadero desafío, señala, no es sostener lo ya logrado, sino crear las condiciones para que la próxima generación de científicos chilenos pueda construir algo igualmente significativo.
Alexis Kalergis se convirtió en el primer chileno en recibir el Distinguished PhD Alumnus Award del Albert Einstein College of Medicine de Nueva York, una distinción que no se solicita sino que se otorga por nominación de la propia comunidad científica internacional. El galardón reconoció sus contribuciones a la inmunología, su liderazgo en investigación de enfermedades infecciosas y su papel central en el diseño de estrategias de vacunación durante la pandemia de COVID-19. Kalergis dirige el Instituto Milenio de Inmunología e Inmunoterapia de Chile y ocupa una posición académica en la Pontificia Universidad Católica de Chile.
Fue precisamente en el Albert Einstein College donde Kalergis realizó su doctorado, una formación que describe como fundacional para su manera de entender la ciencia: como un puente entre la investigación básica, la innovación tecnológica y la aplicación clínica. Ese enfoque guió el desarrollo de una vacuna contra el virus sincicial respiratorio que hoy avanza en ensayos clínicos internacionales, y orientó su liderazgo durante la pandemia, cuando Chile emergió como referente mundial en vacunación basada en evidencia.
Al recibir el premio, Kalergis eligió hablar en plural. Lo presentó como demostración del potencial de la ciencia chilena cuando existen capacidades humanas sólidas, trabajo colaborativo y visión de largo plazo. Pero junto a la celebración llegó una advertencia: la ciencia no florece por el talento individual, sino por ecosistemas —estudiantes, técnicos, investigadores, agencias estatales— que requieren financiamiento estable y continuidad institucional para sostenerse.
Kalergis, quien también es vicepresidente de la Academia Chilena de Ciencias, llamó a profundizar la integración entre universidades, sector productivo y gobierno. Sin ese tejido conectivo, advirtió, incluso los investigadores más destacados ven su trabajo limitado. El premio reconoció lo que ya fue construido. El desafío más difícil, sugirió, es edificar ahora las condiciones para que la próxima generación pueda ir aún más lejos.
Alexis Kalergis received word that he had become the first Chilean to win the Distinguished PhD Alumnus Award from Albert Einstein College of Medicine in New York. The honor arrived not through application but through nomination—a recognition extended by the international scientific community to researchers whose work has shaped biomedicine, biotechnology, and human health. Kalergis, who directs Chile's Millennium Institute in Immunology and Immunotherapy and holds an academic position at the Pontifical Catholic University of Chile, learned that the award specifically acknowledged his contributions to immunology, his leadership in infectious disease research, and his pivotal role in designing immunization strategies that reached across borders. His work during the COVID-19 pandemic figured prominently in the recognition.
The Albert Einstein College of Medicine stands among the world's most influential biomedical research institutions. Kalergis completed his doctoral training there, an experience he credits with teaching him how to bind together basic science, technological innovation, and clinical application—a philosophy that has guided his career back in Chile. Among his most significant achievements is the development of a vaccine against respiratory syncytial virus, which has advanced into international clinical trials. During the pandemic, his leadership proved essential in evaluating SARS-CoV-2 vaccines, positioning Chile among the world's leaders in evidence-based vaccination approaches.
When Kalergis spoke publicly about the award, he framed it not as personal triumph but as evidence of what Chilean science could accomplish. "Being the first Chilean to receive this distinction shows the potential that science developed in Chile possesses when there are solid human capacities, collaborative work, and long-term vision," he said. The statement carried weight beyond ceremony. Kalergis also serves as vice president of the Chilean Academy of Sciences, a role that keeps him attuned to the structural conditions that allow research to flourish or falter.
Yet the award arrived alongside a warning. Kalergis emphasized that science does not emerge from individual brilliance alone but from an ecosystem—students, technicians, researchers, and state agencies including the Ministry of Science and Corfo, Chile's development agency. That ecosystem, he cautioned, faces real vulnerabilities. The most pressing challenge, in his assessment, is securing stable and sustained funding for research and development. Science demands continuity and institutional strength, neither of which emerges from year-to-year uncertainty.
He called for deeper integration among universities, the productive sector, and government—the connective tissue that transforms knowledge into concrete solutions for public health. Without it, even accomplished researchers find their work constrained. The award recognized what Kalergis had already built. The harder work, he suggested, lies ahead: building the conditions that allow the next generation of Chilean scientists to build something equally consequential.
Notable Quotes
Being the first Chilean to receive this distinction shows the potential that science developed in Chile possesses when there are solid human capacities, collaborative work, and long-term vision— Alexis Kalergis
Science requires continuity and institutional strength. Chile must strengthen stable research funding and collaboration between universities, industry, and government— Alexis Kalergis
The Hearth Conversation Another angle on the story
Why does an award from a New York institution matter so much for a Chilean scientist?
Because it signals that work done here is being watched and valued by the world's most rigorous scientific communities. It breaks a certain invisibility. Chile does serious science, but that fact doesn't always travel.
The source emphasizes that this wasn't something he applied for. Why is that distinction important?
Nominations carry different weight than applications. They mean the scientific community itself decided he belonged in that conversation. There's no self-promotion involved. It's peer recognition.
He mentions an ecosystem—students, technicians, agencies. Why does he keep returning to that idea?
Because he knows that individual achievement is a story we tell ourselves. The vaccine work, the pandemic response—none of that happens without infrastructure. And Chile's infrastructure is fragile.
What's the real problem he's identifying when he talks about funding?
Instability. A researcher can't build a long-term program if money arrives in fragments. You lose people. You lose momentum. You can't attract talent if you can't promise continuity.
Does winning this award actually solve any of those problems?
No. It validates the work and raises the profile. But it doesn't change the funding structure or the institutional fragility. It's recognition of what exists, not a solution to what's missing.